JP6605485B2 - ブプロピオンまたは関連組成物およびデキストロメトルファンを含む組成物 - Google Patents

ブプロピオンまたは関連組成物およびデキストロメトルファンを含む組成物 Download PDF

Info

Publication number
JP6605485B2
JP6605485B2 JP2016552474A JP2016552474A JP6605485B2 JP 6605485 B2 JP6605485 B2 JP 6605485B2 JP 2016552474 A JP2016552474 A JP 2016552474A JP 2016552474 A JP2016552474 A JP 2016552474A JP 6605485 B2 JP6605485 B2 JP 6605485B2
Authority
JP
Japan
Prior art keywords
dextromethorphan
bupropion
day
prodrug
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016552474A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016535786A5 (enExample
JP2016535786A (ja
Inventor
タビュトー、ヘリオット
Original Assignee
アンテシップ バイオベンチャーズ トゥー エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アンテシップ バイオベンチャーズ トゥー エルエルシー filed Critical アンテシップ バイオベンチャーズ トゥー エルエルシー
Publication of JP2016535786A publication Critical patent/JP2016535786A/ja
Publication of JP2016535786A5 publication Critical patent/JP2016535786A5/ja
Priority to JP2019189318A priority Critical patent/JP6927601B2/ja
Application granted granted Critical
Publication of JP6605485B2 publication Critical patent/JP6605485B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2016552474A 2013-11-05 2014-11-05 ブプロピオンまたは関連組成物およびデキストロメトルファンを含む組成物 Active JP6605485B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019189318A JP6927601B2 (ja) 2013-11-05 2019-10-16 ブプロピオンまたは関連組成物およびデキストロメトルファンを含む組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361900354P 2013-11-05 2013-11-05
US61/900,354 2013-11-05
PCT/US2014/064184 WO2015069809A1 (en) 2013-11-05 2014-11-05 Compositions and methods comprising bupropion or related compounds and dextromethorphan

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019189318A Division JP6927601B2 (ja) 2013-11-05 2019-10-16 ブプロピオンまたは関連組成物およびデキストロメトルファンを含む組成物および方法

Publications (3)

Publication Number Publication Date
JP2016535786A JP2016535786A (ja) 2016-11-17
JP2016535786A5 JP2016535786A5 (enExample) 2017-03-09
JP6605485B2 true JP6605485B2 (ja) 2019-11-13

Family

ID=53042051

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016552474A Active JP6605485B2 (ja) 2013-11-05 2014-11-05 ブプロピオンまたは関連組成物およびデキストロメトルファンを含む組成物
JP2019189318A Active JP6927601B2 (ja) 2013-11-05 2019-10-16 ブプロピオンまたは関連組成物およびデキストロメトルファンを含む組成物および方法
JP2021124094A Pending JP2021169527A (ja) 2013-11-05 2021-07-29 ブプロピオンおよびデキストロメトルファンの使用
JP2023122146A Pending JP2023129646A (ja) 2013-11-05 2023-07-27 ブプロピオンおよびデキストロメトルファンの使用
JP2025160293A Pending JP2025175199A (ja) 2013-11-05 2025-09-26 ブプロピオンとデキストロメトルファンの組み合わせの使用

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2019189318A Active JP6927601B2 (ja) 2013-11-05 2019-10-16 ブプロピオンまたは関連組成物およびデキストロメトルファンを含む組成物および方法
JP2021124094A Pending JP2021169527A (ja) 2013-11-05 2021-07-29 ブプロピオンおよびデキストロメトルファンの使用
JP2023122146A Pending JP2023129646A (ja) 2013-11-05 2023-07-27 ブプロピオンおよびデキストロメトルファンの使用
JP2025160293A Pending JP2025175199A (ja) 2013-11-05 2025-09-26 ブプロピオンとデキストロメトルファンの組み合わせの使用

Country Status (12)

Country Link
EP (3) EP3981404A1 (enExample)
JP (5) JP6605485B2 (enExample)
KR (4) KR102264179B1 (enExample)
CN (7) CN110279682A (enExample)
AU (7) AU2014346807B2 (enExample)
CA (4) CA3154845C (enExample)
IL (3) IL298972A (enExample)
MX (3) MX373330B (enExample)
MY (1) MY179696A (enExample)
NZ (1) NZ758428A (enExample)
SG (4) SG10201911816XA (enExample)
WO (1) WO2015069809A1 (enExample)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11344544B2 (en) 2013-11-05 2022-05-31 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11969421B2 (en) 2013-11-05 2024-04-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US20220233470A1 (en) 2013-11-05 2022-07-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11596627B2 (en) 2013-11-05 2023-03-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11478468B2 (en) 2013-11-05 2022-10-25 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11497721B2 (en) 2013-11-05 2022-11-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11229640B2 (en) 2013-11-05 2022-01-25 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US11617747B2 (en) 2013-11-05 2023-04-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11197839B2 (en) 2013-11-05 2021-12-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11147808B2 (en) 2013-11-05 2021-10-19 Antecip Bioventures Ii Llc Method of decreasing the fluctuation index of dextromethorphan
US11571399B2 (en) 2013-11-05 2023-02-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11426401B2 (en) 2013-11-05 2022-08-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11357744B2 (en) 2013-11-05 2022-06-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11253492B2 (en) 2013-11-05 2022-02-22 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11617728B2 (en) 2013-11-05 2023-04-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11382874B2 (en) 2013-11-05 2022-07-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11311534B2 (en) 2013-11-05 2022-04-26 Antecip Bio Ventures Ii Llc Bupropion as a modulator of drug activity
US11234946B2 (en) 2013-11-05 2022-02-01 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11273133B2 (en) 2013-11-05 2022-03-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11510918B2 (en) 2013-11-05 2022-11-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11291665B2 (en) 2013-11-05 2022-04-05 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11590124B2 (en) 2013-11-05 2023-02-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11524007B2 (en) 2013-11-05 2022-12-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11123344B2 (en) 2013-11-05 2021-09-21 Axsome Therapeutics, Inc. Bupropion as a modulator of drug activity
US11541048B2 (en) 2013-11-05 2023-01-03 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11253491B2 (en) 2013-11-05 2022-02-22 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11298351B2 (en) 2013-11-05 2022-04-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11207281B2 (en) 2013-11-05 2021-12-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11534414B2 (en) 2013-11-05 2022-12-27 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US20200338022A1 (en) 2019-01-07 2020-10-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11571417B2 (en) 2013-11-05 2023-02-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11541021B2 (en) 2013-11-05 2023-01-03 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11191739B2 (en) 2013-11-05 2021-12-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11298352B2 (en) 2013-11-05 2022-04-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12194006B2 (en) 2013-11-05 2025-01-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11426370B2 (en) 2013-11-05 2022-08-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11517543B2 (en) 2013-11-05 2022-12-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11419867B2 (en) 2013-11-05 2022-08-23 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11129826B2 (en) 2013-11-05 2021-09-28 Axsome Therapeutics, Inc. Bupropion as a modulator of drug activity
US11576877B2 (en) 2013-11-05 2023-02-14 Antecip Bioventures Ii Llc Bupropion as modulator of drug activity
US11439636B1 (en) 2013-11-05 2022-09-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11576909B2 (en) 2013-11-05 2023-02-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
KR102264179B1 (ko) * 2013-11-05 2021-06-11 안테씨프 바이오벤쳐스 투 엘엘씨 부프로피온 또는 관련 화합물과 덱스트로메토르판을 포함하는 조성물 및 방법
US12109178B2 (en) 2013-11-05 2024-10-08 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11364233B2 (en) 2013-11-05 2022-06-21 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11433067B2 (en) 2013-11-05 2022-09-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11285118B2 (en) 2013-11-05 2022-03-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
CN110664801A (zh) * 2014-09-14 2020-01-10 阿瓦尼尔制药股份有限公司 用于治疗痴呆中的激越行为的包含右美沙芬化合物和奎尼丁的药物组合物
HUE052609T2 (hu) 2014-11-21 2021-05-28 Antecip Bioventures Ii Llc Bupropion dextromorfán gyógyszer plazmaszintek modulálására
WO2017165845A1 (en) * 2016-03-24 2017-09-28 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
TWI795446B (zh) * 2017-10-04 2023-03-11 美商神經治療股份有限公司 右旋美索芬(dextromethorphan)經皮輸送裝置
US20230225995A1 (en) * 2019-01-07 2023-07-20 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
CA3223187A1 (en) * 2019-01-07 2020-07-16 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
JP7637150B2 (ja) * 2020-03-30 2025-02-27 アンテシップ バイオベンチャーズ トゥー エルエルシー 神経疾患を治療するためのブプロピオンおよびデキストロメトルファンの組み合わせの使用
US12472156B2 (en) 2020-06-05 2025-11-18 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US12433884B2 (en) 2020-06-05 2025-10-07 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
CN117100750A (zh) * 2020-07-20 2023-11-24 深圳信立泰药业股份有限公司 一种药物组合物及其应用
EP4255433A4 (en) 2020-12-01 2024-05-29 Antecip Bioventures II LLC BUPROPION AND DEXTROMETHROPHANE TO REDUCE THE RISK OF SUICIDE IN PATIENTS WITH DEPRESSION
CN116981450A (zh) * 2021-01-18 2023-10-31 安泰赛普生物风投二代有限责任公司 抗抑郁剂和和右美沙芬的组合用于治疗神经精神病症
CN112999350A (zh) * 2021-02-23 2021-06-22 北京斯利安药业有限公司 一种药物组合物、复方制剂及其制备方法与应用
US11717518B1 (en) 2022-06-30 2023-08-08 Antecip Bioventures Ii Llc Bupropion dosage forms with reduced food and alcohol dosing effects
CN118785900A (zh) * 2022-06-30 2024-10-15 艾克萨姆治疗公司 包含安非他酮和半胱氨酸的药物组合物
US12036191B1 (en) 2022-06-30 2024-07-16 Antecip Bioventures Ii Llc Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan
US12156914B2 (en) 2022-06-30 2024-12-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising bupropion and cysteine
US11730706B1 (en) 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations
US11844797B1 (en) 2023-04-20 2023-12-19 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US12194036B2 (en) 2022-07-07 2025-01-14 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350756A (en) * 1991-06-17 1994-09-27 Smith Richard A Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan
WO1998050044A1 (en) * 1997-05-07 1998-11-12 Algos Pharmaceutical Corporation Composition and method combining an antidepressant with an nmda receptor antagonist, for treating neuropathic pain
US6207674B1 (en) * 1999-12-22 2001-03-27 Richard A. Smith Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants
US6780871B2 (en) * 2001-01-29 2004-08-24 Albany Medical College Methods and compositions for treating addiction disorders
TWI326214B (en) * 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
AU2007212586A1 (en) * 2006-02-03 2007-08-16 Avanir Pharmaceuticals Pharmaceutical compositions for treating depression, anxiety and neurodegenerative disorders
WO2009006194A1 (en) * 2007-06-28 2009-01-08 Avanir Pharmaceuticals Pharmaceutical compositions for the treatment of involuntary emotional expression disorder
WO2012118562A1 (en) * 2011-03-02 2012-09-07 Rhine Pharmaceuticals, Llc Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations
US20130274282A1 (en) * 2012-04-16 2013-10-17 Herriot Tabuteau Compositions and methods comprising celecoxib or related compounds and dextromethorphan
KR102264179B1 (ko) * 2013-11-05 2021-06-11 안테씨프 바이오벤쳐스 투 엘엘씨 부프로피온 또는 관련 화합물과 덱스트로메토르판을 포함하는 조성물 및 방법

Also Published As

Publication number Publication date
MX2016005867A (es) 2016-07-15
MX373330B (es) 2020-05-04
SG10201911816XA (en) 2020-01-30
CA3256217A1 (en) 2025-10-30
IL283760B2 (en) 2023-05-01
CA3154845A1 (en) 2015-05-14
AU2019236614A1 (en) 2019-10-17
AU2025230795A1 (en) 2025-10-02
MX2020004075A (es) 2021-12-10
EP3981404A1 (en) 2022-04-13
IL245504B (en) 2021-06-30
SG11201603391XA (en) 2016-05-30
CN113750098A (zh) 2021-12-07
MY179696A (en) 2020-11-11
KR20220054909A (ko) 2022-05-03
WO2015069809A1 (en) 2015-05-14
CN110327338A (zh) 2019-10-15
CA2929415C (en) 2023-01-03
NZ719892A (en) 2021-07-30
KR102603013B1 (ko) 2023-11-15
EP3065742A1 (en) 2016-09-14
NZ758425A (en) 2021-07-30
AU2014346807A1 (en) 2016-05-19
IL283760B1 (en) 2023-01-01
CA3154845C (en) 2023-02-28
MX388666B (es) 2025-03-20
JP2021169527A (ja) 2021-10-28
JP2025175199A (ja) 2025-11-28
JP6927601B2 (ja) 2021-09-01
CN113750099A (zh) 2021-12-07
JP2016535786A (ja) 2016-11-17
NZ758428A (en) 2021-07-30
JP2020023543A (ja) 2020-02-13
KR102264179B1 (ko) 2021-06-11
AU2023203438A1 (en) 2023-07-06
AU2021202497B2 (en) 2023-03-02
KR20160070158A (ko) 2016-06-17
IL245504A0 (en) 2016-06-30
CA3175703A1 (en) 2015-05-14
CN110279682A (zh) 2019-09-27
NZ758432A (en) 2021-07-30
AU2019236614C1 (en) 2021-10-14
CN113797205A (zh) 2021-12-17
EP3065742A4 (en) 2017-04-05
CA2929415A1 (en) 2015-05-14
SG10201810888XA (en) 2019-01-30
AU2019236614B2 (en) 2021-07-15
CN110251517A (zh) 2019-09-20
KR20230148385A (ko) 2023-10-24
AU2019275593A1 (en) 2020-01-02
IL283760A (en) 2021-07-29
JP2023129646A (ja) 2023-09-14
AU2023203438B2 (en) 2025-06-26
SG10201911808QA (en) 2020-01-30
KR20210068157A (ko) 2021-06-08
NZ758431A (en) 2021-07-30
IL298972A (en) 2023-02-01
AU2018203638A1 (en) 2018-06-14
CN106163522A (zh) 2016-11-23
AU2018203638B2 (en) 2019-07-18
MX2021015234A (es) 2022-05-26
EP3981403A1 (en) 2022-04-13
AU2019275593B2 (en) 2021-01-28
AU2021202497A1 (en) 2021-05-27
AU2018203638C1 (en) 2019-10-24
CA3175703C (en) 2025-08-05
AU2014346807B2 (en) 2018-03-22

Similar Documents

Publication Publication Date Title
JP6605485B2 (ja) ブプロピオンまたは関連組成物およびデキストロメトルファンを含む組成物
JP2020023543A6 (ja) ブプロピオンまたは関連組成物およびデキストロメトルファンを含む組成物および方法
JP6842129B2 (ja) ブプロピオンまたは関連組成物およびデキストロメトルファンを含む組成物および方法
US9457025B2 (en) Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
US9370513B2 (en) Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
HK40063444A (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
HK40064612A (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
HK40063443A (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
HK40014888A (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
HK40014464A (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
HK40015601A (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170904

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180807

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190402

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190917

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191016

R150 Certificate of patent or registration of utility model

Ref document number: 6605485

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250